Idelalisib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 150 mg
Reference Brands: Zydelig (EU/UK/India)
Category:
Oncology Cancer Care
Idelalisib is available in Tablets
and strengths such as 100 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Idelalisib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Idelalisib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Idelalisib is an oral targeted anticancer medication used in the treatment of certain hematologic malignancies, particularly B-cell cancers. It is primarily indicated for patients with relapsed chronic lymphocytic leukemia (CLL) and is often administered in combination with rituximab when previous treatments have not been effective. Idelalisib is also used for relapsed follicular lymphoma and small lymphocytic lymphoma in patients who have received prior therapies.
Idelalisib works by selectively inhibiting the phosphoinositide 3-kinase delta (PI3K-δ) enzyme, a key component of a signaling pathway that promotes the growth, survival, and migration of malignant B-cells. By blocking this pathway, the drug helps slow the progression of cancer cells and may induce their death, thereby improving disease control in affected patients.
Idelalisib belongs to the class of medicines known as kinase inhibitors and represents an important advancement in targeted cancer therapy. It is marketed under the brand name Zydelig and is available in oral tablet form. Due to its targeted mechanism of action, Idelalisib has become a valuable treatment option in modern oncology, particularly for patients who require alternative therapies after relapse or resistance to conventional treatments.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing